BR112023024571A2 - Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos - Google Patents

Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos

Info

Publication number
BR112023024571A2
BR112023024571A2 BR112023024571A BR112023024571A BR112023024571A2 BR 112023024571 A2 BR112023024571 A2 BR 112023024571A2 BR 112023024571 A BR112023024571 A BR 112023024571A BR 112023024571 A BR112023024571 A BR 112023024571A BR 112023024571 A2 BR112023024571 A2 BR 112023024571A2
Authority
BR
Brazil
Prior art keywords
chk1
inhibitors
checkpoint kinase
methods
checkpoint
Prior art date
Application number
BR112023024571A
Other languages
English (en)
Inventor
b pinkerton Anthony
Jacques Mauger
Janette Elsdon Rachelle
Todd Meyer Stephen
Pham Hong Truong Yen
Original Assignee
Boundless Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boundless Bio Inc filed Critical Boundless Bio Inc
Publication of BR112023024571A2 publication Critical patent/BR112023024571A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos. são fornecidos nesse documento compostos e métodos para o tratamento de câncer. os métodos incluem a administração a um indivíduo em necessidade dos mesmos de uma quantidade terapeuticamente eficaz de um inibidor de chk1 divulgado nesse documento.
BR112023024571A 2021-05-27 2022-05-26 Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos BR112023024571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163193990P 2021-05-27 2021-05-27
PCT/US2022/031141 WO2022251502A1 (en) 2021-05-27 2022-05-26 Checkpoint kinase 1 (chk1) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112023024571A2 true BR112023024571A2 (pt) 2024-02-06

Family

ID=84229213

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024571A BR112023024571A2 (pt) 2021-05-27 2022-05-26 Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos

Country Status (10)

Country Link
US (2) US11707462B2 (pt)
EP (1) EP4347582A1 (pt)
KR (1) KR20240021188A (pt)
CN (1) CN117715905A (pt)
AU (1) AU2022282384A1 (pt)
BR (1) BR112023024571A2 (pt)
CA (1) CA3219348A1 (pt)
IL (1) IL308759A (pt)
TW (1) TW202313588A (pt)
WO (1) WO2022251502A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021188A (ko) 2021-05-27 2024-02-16 바운드리스 바이오, 인크. 체크포인트 키나제 1(chk1) 억제제 및 그의 용도
WO2023120696A1 (ja) * 2021-12-24 2023-06-29 住友ファーマ株式会社 二環性骨格を有する１ｈ－ピラゾール－３－アミン誘導体
WO2023230477A1 (en) * 2022-05-24 2023-11-30 Boundless Bio, Inc. Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof
WO2023226658A1 (en) * 2022-05-25 2023-11-30 Sperogenix Therapeutics Limited Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249865A1 (en) * 2000-04-18 2001-10-30 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
US20050209297A1 (en) * 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
PA8850801A1 (es) 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
SI3411036T1 (sl) * 2016-02-04 2022-03-31 Pharmaengine, Inc. 3,5-disubstituirani pirazoli, uporabni kot kontrolne točke inhibitorjev kinaze 1 (CHK1), ter njihovi pripravki in uporaba
EP4007757A4 (en) * 2019-08-01 2023-07-19 Integral Biosciences Pvt. Ltd. HETEROCYCLIC COMPOUND AS KINASE INHIBITORS AND USES THEREOF
CN112457306A (zh) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN111253370B (zh) 2020-03-24 2021-08-03 浙江大学 N-多取代吡啶-2-氨基嘧啶类衍生物及用途
BR112022025732A2 (pt) * 2020-06-19 2023-03-07 Anaxis Pharma Pty Ltd Compostos de sulfonamida
CN116368243A (zh) 2020-08-12 2023-06-30 无界生物公司 复制应激通路剂组合物和用于治疗癌症的方法
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
JP7082256B1 (ja) * 2020-11-30 2022-06-07 住友ファーマ株式会社 ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体
KR20240021188A (ko) 2021-05-27 2024-02-16 바운드리스 바이오, 인크. 체크포인트 키나제 1(chk1) 억제제 및 그의 용도

Also Published As

Publication number Publication date
EP4347582A1 (en) 2024-04-10
US11707462B2 (en) 2023-07-25
CA3219348A1 (en) 2022-12-01
US20230026313A1 (en) 2023-01-26
TW202313588A (zh) 2023-04-01
AU2022282384A1 (en) 2023-12-14
WO2022251502A1 (en) 2022-12-01
CN117715905A (zh) 2024-03-15
KR20240021188A (ko) 2024-02-16
IL308759A (en) 2024-01-01
US20230310423A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
BR112023024571A2 (pt) Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112016008593A8 (pt) composto, composição farmacêutica, método de regulação de transcrição gênica em uma célula, uso de um composto e método de inibição de reconhecimento mediado por bromodomínio de uma região de acetil lisina de uma proteína
BR112021023359A2 (pt) Inibidores de g12c de kras e usos dos mesmos
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
BR112022002698A2 (pt) Compostos de imidazolil pirimidinilamina como inibidores de cdk2
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
BR112021017583A2 (pt) Compostos, composições e métodos para o tratamento de doença
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
CR20190361A (es) Dendrímeros terapéuticos
BR112022002905A2 (pt) Composições e métodos para modular splicing e expressão de proteína
BR112023024942A2 (pt) Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
BR112022008365A2 (pt) Inibidores de cd73
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2
BR112021019703A2 (pt) Compostos heterocíclicos e usos dos mesmos
BR112017018198A2 (pt) inibição da atividade de olig2